Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMMIT: mFOLFOX6/Bevacizumab/Atezolizumab vs Atezolizumab in First-Line dMMR/MSI-H Metastatic Colorectal Cancer
NCT02997228Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2018
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in colorectal cancer (CRC), sponsored by National Cancer Institute. Started Jan 2018; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02997228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997228.